Melinta Therapeutics Announces Publication of an Independent Review of Delafloxacin Clinical Results and Pharmacokinetics

Company Notice – Melinta Therapeutics today reported that an independent investigator, Dr. Matteo Bassetti of the Azienda Ospedaliero-Universitaria in Udine, Italy, has published a review of delafloxacin’s microbiological activity and pharmacokinetic data. Delafloxacin is an investigational fluoroquinolone being developed by Melinta for the treatment of patients with acute bacterial skin and skin structure infections (ABSSSI). The article, titled Delafloxacin for the treatment of respiratory and skin infections, may be accesses online in the journal, Expert Opinion on Investigational Drugs, or by visiting the list of Publications on the Melinta website.

About Delafloxacin

Delafloxacin, is an investigational fluoroquinolone antibiotic currently in Phase 3 clinical development for ABSSSI. The PROCEED studies (studies 302 and 303) are Phase 3, multicenter, randomized, double-blind, active-controlled trials to evaluate the efficacy and safety of delafloxacin compared with vancomycin + aztreonam in patients with acute bacterial skin and skin structure infections.

About Melinta Therapeutics

Melinta Therapeutics, Inc. is dedicated to the discovery, development and commercialization of groundbreaking antibiotics to overcome drug-resistant, life-threatening infections. The need for new therapies for drug-resistant infections is widely recognized as one of the most serious public health issues facing the world today. To meet this need, Melinta Therapeutics is rapidly progressing its late-stage investigational antibiotic, delafloxacin, which is currently in Phase 3 development for acute bacterial skin and skin structure infections (ABSSSI). Delafloxacin has been designated a Qualified Infectious Disease Product (QIDP) for both ABSSSI and community-acquired bacterial pneumonia by the U.S. Food and Drug Administration. A key initiative at Melinta is to develop, through the application of Nobel Prize-winning science, a new class of antibiotics designed to overcome the drug-resistant ESKAPE pathogens known to cause serious hospital infections. Melinta Therapeutics is privately held and backed by lead investor Vatera Healthcare Partners among other private investors. The company is headquartered in New Haven, CT with offices in Lincolnshire, IL. Visit www.melinta.com for more information.

 

NOITE: The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.